Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on May 18, 2010, reporting an event that occurred on May 17, 2010. The Company is a biopharmaceutical firm incorporated in Florida with principal executive offices in Carmiel, Israel.
Key Financial Metrics
This filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific non-operational event.
Material Changes
The material change reported is the award of a government grant. On May 17, 2010, the Office of the Chief Scientist (OCS) of Israel's Ministry of Industry, Trade and Labor awarded the Company a grant of up to $4.1 million for calendar year 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items beyond the announcement of the grant award.
Investor Verification Checklist
- Verify the specific terms and conditions attached to the $4.1 million grant from the Office of the Chief Scientist.
- Confirm the timeline for the disbursement of grant funds throughout calendar year 2010.
- Review the attached press release (Exhibit 99.1) for details on the specific research or development projects funded by this grant.